Ask AI
ProCE Banner Activity

CAR T-Cell Therapy: What Oncology Nurses Need to Know About Long-Term AEs

Clinical Thought

As data have continued to evolve, CAR T-cell therapy has expanded into earlier lines of treatment and important FDA safety and monitoring updates are reshaping postinfusion care. Let’s talk about practical, nurse-centered guidance for patient selection, acute toxicity recognition, and long-term surveillance for cytopenias, infections/hypogammaglobulinemia, and delayed neurologic effects.

Released: December 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals who care for patients treated with CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients at increased risk for long-term toxicities related to CAR T-cell therapy

  • Counsel patients and caregivers on the onset, symptoms, and clinical manifestations of short-term vs long-term toxicities related to CAR T-cell therapy

  • Implement strategies to monitor for and manage long-term toxicities in patients treated with CAR T-cell therapy based on the latest guidelines, expert recommendations, and evidence

  • Develop plans for transitioning care from the CAR T-cell treating center to community practice that optimize the patient’s long-term safety and quality of life

Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi.